ACADIA Pharmaceuticals Inc. (ACAD)

28.05
NASDAQ : Health Technology
Prev Close 29.21
Day Low/High 27.90 / 29.62
52 Wk Low/High 13.17 / 30.38
Avg Volume 1.23M
Exchange NASDAQ
Shares Outstanding 144.49M
Market Cap 4.22B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study Of Pimavanserin For Alzheimer's Disease Psychosis

ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study Of Pimavanserin For Alzheimer's Disease Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced positive top-line results from its Phase II exploratory study (-019 Study) of pimavanserin in patients with Alzheimer's disease psychosis (AD Psychosis).

Allergan, Apple, Oakland Capital: Doug Kass' Views

Allergan, Apple, Oakland Capital: Doug Kass' Views

Doug Kass shares his thoughts on China and life insurers.

This Rally May Not Be Done, but It's Close

Friday’s action was enough for me to believe we’re near a real pullback.

Apple, Starbucks, Cisco: Doug Kass' Views

Apple, Starbucks, Cisco: Doug Kass' Views

Doug Kass shares his thoughts on a strange, possibly ominous day, and a 'ludicrous forecast.'

ACADIA Pharmaceuticals Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Major Depressive Disorder

ACADIA Pharmaceuticals Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Major Depressive Disorder

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system (CNS) disorders, today announced the initiation of CLARITY,...

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Doug Kass shares his thoughts on the Trump world and how large-cap biotechs are doing.

Apple Continues to Underperform; the Market Is Resistant: Best of Kass

Apple Continues to Underperform; the Market Is Resistant: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us about how Apple is still a short for him and that the market is still resistant.

Biotech Hits an Inflection Point

Biotech Hits an Inflection Point

The worst appears to be over for this sector; we could see big growth ahead.

4 Promising Small Biotechs to Watch in 2017

4 Promising Small Biotechs to Watch in 2017

Veterinary drug play Aratana Therapeutics is among the potential solid performers next year.

2 Small-Cap Biotech Buyout Targets

2 Small-Cap Biotech Buyout Targets

With the election resolved, biotech could be ripe for consolidation.

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

Pharma stocks have bounced back from their prior selloff, but whether they will continue their upward trend under a Donald Trump administration remains unclear.

ACADIA Pharmaceuticals Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Negative Symptoms Of Schizophrenia

ACADIA Pharmaceuticals Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Negative Symptoms Of Schizophrenia

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system disorders, today announced the initiation of ADVANCE, a...

Acadia Shares Soar as Nuplazid Sales Easily Top Estimates

Acadia Shares Soar as Nuplazid Sales Easily Top Estimates

Acadia reported sales of its treatment for hallucinations associated with Parkinson's disease that more than doubled estimates in the third quarter.

Analysts' Actions -- Bank of America, Depomed, Hertz, AT&T and More

Analysts' Actions -- Bank of America, Depomed, Hertz, AT&T and More

Here are Tuesday's top research calls, including downgrades for Bank of America, Depomed, Hertz and AT&T.

ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results

ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

Cisco, Allergan, Facebook: Doug Kass' Views

Cisco, Allergan, Facebook: Doug Kass' Views

Doug Kass shares his thoughts on the bond market's bounciness and stocks suffering election uncertainty.

ACADIA Pharmaceuticals Initiates Phase III Trial Of Pimavanserin For Adjunctive Treatment In Patients With Schizophrenia

ACADIA Pharmaceuticals Initiates Phase III Trial Of Pimavanserin For Adjunctive Treatment In Patients With Schizophrenia

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system disorders, today announced the initiation of ENHANCE-1, a...

Small Biotechs on My Shopping List

Small Biotechs on My Shopping List

These small-caps are woefully undervalued after getting shellacked in October.

ACADIA Pharmaceuticals To Announce Third Quarter 2016 Financial Results On November 7, 2016

ACADIA Pharmaceuticals To Announce Third Quarter 2016 Financial Results On November 7, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Initiates Phase II Study Of Pimavanserin In Alzheimer's Disease Agitation

ACADIA Pharmaceuticals Initiates Phase II Study Of Pimavanserin In Alzheimer's Disease Agitation

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system disorders, today announced the initiation of SERENE, a...

Schlumberger, Amazon, Apple: Doug Kass' Views

Schlumberger, Amazon, Apple: Doug Kass' Views

Doug Kass shares his thoughts on 'stuck' markets and on differing risk appetites and timeframes.

Biotech Bargain Bin Bursts With Bounty

Biotech Bargain Bin Bursts With Bounty

This sector is one of the few areas of the market where you'll find myriad compelling values.

ACADIA Pharmaceuticals Receives California Life Sciences Association's 2016 Pantheon DiNA Award For Outstanding Therapeutic Product For NUPLAZID™

ACADIA Pharmaceuticals Receives California Life Sciences Association's 2016 Pantheon DiNA Award For Outstanding Therapeutic Product For NUPLAZID™

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders,...

J.C.Penney, Wells Fargo, Deutsche Bank: Doug Kass' Views

J.C.Penney, Wells Fargo, Deutsche Bank: Doug Kass' Views

Doug Kass shares his thoughts on the banks and looks back on 20 years with TheStreet.

ACADIA Pharmaceuticals To Present At The Ladenburg Thalmann 2016 Healthcare Conference On September 27, 2016

ACADIA Pharmaceuticals To Present At The Ladenburg Thalmann 2016 Healthcare Conference On September 27, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Sponsors National Parkinson Foundation's Caregiver Summit

ACADIA Pharmaceuticals Sponsors National Parkinson Foundation's Caregiver Summit

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders, is...

These 5 Biotech Stocks Are Ready for a Volatility Break

These 5 Biotech Stocks Are Ready for a Volatility Break

The squeeze is on these stocks, and they are poised for volatile moves.

Don't Be Fooled, There's Still Complacency Here

We should rebound and then come back down again.

5 Stocks to Trade for Big Breakout Gains

5 Stocks to Trade for Big Breakout Gains

These stocks are within range of triggering big breakout trades.

TheStreet Quant Rating: D (Sell)